Economic Analyses to Inform and Support Health Policy for Chronic Hepatitis B Treatment
- 16 Downloads
Purpose of Review
Summarize insights into the economic impact of global hepatitis B treatment policies.
With the highly effective antiviral treatment, entecavir and recently tenofovir, coming off patent, hepatitis B treatment is now very inexpensive and may save costs in the long run. In the USA alone, dramatic increases in screening and treatment would prevent between 80 and 100 thousand cases of cirrhosis, 50 and 60 thousand cases of liver cancer, and 80 to 100 thousand HBV-related deaths over the next 50 years.
Cost-effectiveness analyses can provide information in the form of what a proper course of action will cost, and what the benefits will be in terms of health impact. Since the sharp reduction in antiviral drug pricing, the focus should be on treating patients with generic antivirals to ensure that the chronic hepatitis B care and treatment efforts are highly cost-effective and even cost-saving.
KeywordsHepatitis B treatment Cost-effectiveness Health policy Economic analyses
Compliance with Ethical Standards
Conflict of Interest
Mehlika Toy, David W. Hutton, and Samuel So each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.•• WHO. Global Hepatitis Report 2017. Geneva2017. Report No.: Licence: CC BY-NC-SA 3.0IGO.The first global hepatitis report, which provides a baseline for the drive towards elimination. The report contains global data on viral hepatitis B and C. Google Scholar
- 2.WHO. Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards Ending Viral Hepatitis 2016.Google Scholar
- 3.Organization WH. Viral hepatitis strategic information and modelling reference group: meeting report. Meeting report 14–16 June 2016, WHO headquarters, Geneva, Switzerland, vol. 2016. Switzerland: WHO headquarters Geneva.Google Scholar
- 6.European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. https://doi.org/10.1016/j.jhep.2017.03.021.CrossRefGoogle Scholar
- 7.Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. WHO guidelines approved by the guidelines review committee. Geneva 2015.Google Scholar
- 8.• Hutin Y, Nasrullah M, Easterbrook P, Nguimfack BD, Burrone E, Averhoff F, et al. Access to treatment for hepatitis B virus infection - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(28):773–7. https://doi.org/10.15585/mmwr.mm6728a2 Important review summarizing access to treatment of hepatitis B infection worldwide. CrossRefGoogle Scholar
- 9.Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.Google Scholar
- 17.Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E. P TK et al. cost-effectiveness analysis of alternative antiviral strategies for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B in the United Kingdom. Value Health. 2015;18(6):800–9. https://doi.org/10.1016/j.jval.2015.05.007.CrossRefGoogle Scholar
- 18.Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of hepatitis B virus infection screening and treatment or vaccination in 6 high-risk populations in the United States. Open Forum Infect Dis. 2019;6(1):ofy353. https://doi.org/10.1093/ofid/ofy353.CrossRefGoogle Scholar
- 19.• Toy M, Hutton DW, So S. Population health and economic impacts of reaching chronic hepatitis B diagnosis and treatment targets in the US. Health Aff (Millwood). 2018;37(7):1033–40. https://doi.org/10.1377/hlthaff.2018.0035 A modeling study that quantifies screening and treatment to reach the WHO target in 2025 and 2030 in the US. CrossRefGoogle Scholar
- 20.Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in the Gambia: an economic modelling analysis. Lancet Glob Health. 2016;4(8):e568–78. https://doi.org/10.1016/S2214-109X(16)30101-2.CrossRefGoogle Scholar
- 22.•• National Academies of Sciences E, and Medicine. A national strategy for the elimination of hepatitis B and C: phase two report. Washington 2017.Phase two report published by the National Academies that provides recommendations for achievement of US hepatitis B and C targets by 2030. Google Scholar
- 23.• Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, et al. Additional resource needs for viral hepatitis elimination through universal health coverage: Projections in 67 low-income and middle-income countries, 2016–2030. Lancet Global Health. 2019; (In Press). A modeling study that calculates the cost to eliminate hepatitis B and C in 67 high prevalence countries if treatment were included as part of Universal Health Coverage. Google Scholar